Oric Pharmaceuticals, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ORIC presented Phase 1b data for enozertinib in 26 first-line EGFR atypical NSCLC patients (as of Sept 4, 2026), achieving 84% confirmed systemic ORR, 70% confirmed CNS ORR, 88% 6-month PFS, zero treatment discontinuations, and no off-target toxicities. The company plans to initiate Redwood-1, a global Phase 3 trial in 1L EGFR atypical NSCLC, in H1 2027; the addressable US market is ~7,000 patients annually ($2.5B opportunity). End-of-Phase 1 FDA alignment was completed on trial design, patient population, control arm (osimertinib or afatinib), and dual primary endpoints (ORR for accelerated approval, PFS for full approval).
Why this rating
Phase 1b data is encouraging and de-risks Phase 3 initiation for a $2.5B US market opportunity (~3% of company's ~$862M market cap). However, Phase 3 success is uncertain, and enozertinib is still investigational. Early-stage biotech derisk is meaningful but not transformational at this scale.
Tradability signal
NO TRADE
No trade: positive news with only -1.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.38% over 4 hrs, n=234). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $13.27 ▲ 0.15% | at our read · unknown $13.25 | +10 min · unknown $13.02 ▼ 1.74% | +30 min · unknown $12.84 ▼ 3.09% | +1 hr · unknown $12.99 ▼ 1.96% | +4 hrs pending |
The stock had already moved -0.15% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.